Skip to main content
logo
Lonza Group AG (LON:0QNO)
London flag London · Delayed Price · Currency is GBP · Price in CHF
525.17
+7.07 (1.36%)
At close: Mar 4, 2026

Revenue

Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Integrated Biologics Revenue
3.65B2.88B
Integrated Biologics Revenue Growth
26.57%-22.48%
Advanced Synthesis Revenue
1.61B1.32B
Advanced Synthesis Revenue Growth
21.77%46.84%
Specialized Modalities Revenue
1.03B1.10B
Specialized Modalities Revenue Growth
-5.91%57.90%
Corporate Revenue
237.00M175.00M
Corporate Revenue Growth
35.43%-27.08%

Revenue by Geography

Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Europe Revenue
3.14B
Europe Revenue Growth
-4.50%
North and Central America Revenue
2.44B
North and Central America Revenue Growth
8.14%
Latin America Revenue
129.00M
Latin America Revenue Growth
32.99%
Asia Revenue
837.00M
Asia Revenue Growth
-20.29%
Australia & New Zealand Revenue
17.00M
Australia & New Zealand Revenue Growth
6.25%
Other Geographic Revenue
3.00M
Other Geographic Revenue Growth
50.00%

Adjusted EBITDA

Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Integrated Biologics Core EBITDA
1.29B1.05B
Integrated Biologics Core EBITDA Growth
23.16%-20.59%
Advanced Synthesis Core EBITDA
674.00M484.00M
Advanced Synthesis Core EBITDA Growth
39.26%66.32%
Specialized Modalities Core EBITDA
176.00M192.00M
Specialized Modalities Core EBITDA Growth
-8.33%182.35%
Corporate Core EBITDA
-73.00M-68.00M
Updated Dec 31, 2025. Data Source: Fiscal.ai.